Kognition bei depressiven Störungen

Sachs G, Steger-Wuchse D, Kryspin-Exner I, Gur RC, Katschnig H (2004) Facial recognition deficits and cognition in schizophrenia. Schizophr Res 68(1):27–35

Sachs G, Winklbaur B, Jagsch R, Keefe RSE (2011) Validation of the German version of the Brief Assessment of Cognition in Schizophrenia (BACS) – preliminary results. Eur Psychiatry 26(2):74–77

Sachs G, Schaffer M, Winklbaur B (2006) Kognitive Störungen bei bipolaren Erkrankungen. Neuropsychiatrie 21(2):93–101

Sachs G, Winklbaur B, Jagsch R, Lasser I, Kryspin-Exner I, Frommann N, Wölwer W (2012) Training of affect recognition (TAR) in schizophrenia – impact on functional outcome. Schizophr Res 138(2):262–267

Conradi HJ, Ormel J, de Jonge P (2010) Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 41:1165–1174

Trivedi MH, Greer TL (2014) Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord 152–154:19–27

Hammar A, Ardal G (2009) Cognitive functioning in major depression – a summary. Front Hum Neurosci 25(3):26

Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN (2012) Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat 1–6

Lee RSC, Hermens DF, Porter MA, Redoblado-Hodge MA (2012) A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord 140:113–124

Lasser I (2011) Die deutsche Version des Screen for Cognitive Impairment in Psychiatry (SCIP-D): psychometrische Eigenschaften einer kurzen Skala zur Erfassung kognitiver Leistungsfähigkeit bei schizophrenen Patienten. Diplomarbeit, Universität Wien, Fakultät für Psychologie

McIntyre RS, Soczynska JZ, Woldeyohannes HO, Alsuwaidan MT, Cha DS, Carvalho AF, Jerrell JM, Dale RM, Gallaugher LA, Muzina DJ, Kennedy SH (2015) The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry 56:279–282

Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164(6):900–909

Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, Kennedy SH (2014) The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res 220(1–2):245–250

Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27(4):215–223

McIntyre RS, Lophaven S, Olsen CK (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 17(10):1557–1567

Dilling H, Mombour W, Schmidt MH et al. (2013) Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien. 8. Auflage, Huber, Bern

American Psychiatric Association, Falkai P , Wittchen HU (Hrsg) Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. Deutsche Ausgabe. Hogrefe, Göttingen